Licensing status

Publication and contact information



E selectin (SELE; CD62E)

Mouse studies suggest blocking SELE could help prevent neutropenia during chemotherapy or radiation therapy. In mice receiving chemotherapy or radiotherapy, Sele knockout increased hematopoietic stem cell (HSC) survival and leukocyte numbers compared with Sele expression. In wild-type mice receiving chemotherapy, pretreatment with the pan-selectin antagonist GMI-1070 promoted HSC quiescence and self-renewal and neutrophil recovery, and it led to increased survival compared with saline pretreatment. Ongoing work includes designing SELE-specific antagonists and optimizing for bioavailability.
GMI-1070, a pan-selectin inhibitor from GlycoMimetics Inc. and partner Pfizer Inc., is in Phase II testing to treat sickle cell disease.

SciBX 5(44); doi:10.1038/scibx.2012.1160
Published online Nov. 8, 2012

Multiple issued and pending patents covering GMI-1070 and related pan-selectin antagonists; licensed to Pfizer

Winkler, I.G. et al. Nat. Med.; published online Oct. 21, 2012;
Contact: Jean-Pierre Lévesque,
Mater Medical Research Institute, South Brisbane, Queensland, Australia
Contact: Ingrid G. Winkler,
same affiliation as above